APAC Bladder Disorders Market - Industry Trends and Forecast to 2029
- Published Date: 2022-12-22
- Report ID: 143122
- Pages: 225
-
Format:
Short Description
Asia-Pacific Bladder Disorders Market, By Type (Cystitis, Urinary Incontinence, Overactive Bladder, Interstitial Cystitis, Bladder Cancer), Treatment Type (Surgery, Medication, Non-surgical, and others), End User (Hospitals, Clinics, Ambulatory Surgery Centres, Others), Distribution Channel (Direct, Retail) Country (China, Japan, India, South Korea, Australia, Singapore, Thailand, Malaysia, Indonesia, Philippine, Rest of Asia-Pacific) Industry Trends and Forecast to 2029
Market Definition:
Bladder-related disorders include Cystitis - inflammation of the bladder, often from infection, Urinary incontinence - loss of bladder control, Overactive bladder - a condition in which the bladder squeezes urine out at the wrong time, Interstitial cystitis - a chronic problem that causes bladder pain and frequent, urgent urination and bladder cancer.
The doctors perform different tests to diagnose the bladder disorder, including x-rays, urine tests, and a bladder wall examination by scope called a cystoscope. The treatment of the disorder depends on the cause of the problem, including medication, surgeries (in severe cases), and non-surgical procedures.
Anticholinergic medications are the first line of pharmacotherapy for Over-active Bladder (OAB) syndrome. OAB is a clinical symptom characterized by the urgency of the desire to pass urine, which is difficult to defer. Generally, the frequency of passing urine more than eight times per day is considered in OAB. Anticholinergic drugs inhibit the muscarinic receptors at the detrusor muscle, reducing bladder contractility. To reduce the side effects, new medications with improved bladder selectivity and extended-release formulations are being developed. Most of the more recent medications are equally effective at reducing the symptoms of an overactive bladder.
Market Segmentation:
The Asia-Pacific bladder disorders market is categorized into four segments: type, treatment type, end user, and distribution channel.
On the basis of type, the Asia-Pacific bladder disorders market is segmented into Cystitis, Urinary Incontinence, Overactive Bladder, Interstitial Cystitis, Bladder Cancer
On the basis of treatment type, the Asia-Pacific bladder disorders market is segmented into Surgery, Medication, Non-surgical, and others.
On the basis of end-user, the Asia-Pacific bladder disorders market is segmented into Hospitals, Clinics, Ambulatory Surgery Centres, Others
On the basis of distribution channel, the Asia-Pacific bladder disorders market is segmented into direct and retail
Market Players
The major companies which are dealing in the Asia-Pacific bladder disorders market are listed below:
Medtronic
Laborie
Boston Scientific Corporation
Pfizer Inc.
Astellas Pharma Inc.
KYORIN Pharmaceutical Co., Ltd. (A subsidiary of KYORIN Holdings, Inc.)
Bristol-Myers Squibb Company
Johnson & Johnson Services, Inc.
Axonics, Inc.
Merck & Co., Inc.
Viatris Inc.
Gaylord Chemical Company, L.L.C.
Coloplast Corp, AbbVie Inc.
Sun Pharmaceutical Industries Ltd.
Zydus Group
Swati Spentose
Urovant Sciences, among others.
TABLE OF CONTENTS
1 INTRODUCTION 24
1.1 OBJECTIVES OF THE STUDY 24
1.2 MARKET DEFINITION 24
1.3 OVERVIEW OF ASIA PACIFIC BLADDER DISORDERS MARKET 24
1.4 LIMITATIONS 25
1.5 MARKETS COVERED 26
2 MARKET SEGMENTATION 28
2.1 MARKETS COVERED 28
2.2 GEOGRAPHICAL SCOPE 29
2.3 YEARS CONSIDERED FOR THE STUDY 30
2.4 CURRENCY AND PRICING 30
2.5 DBMR TRIPOD DATA VALIDATION MODEL 31
2.6 MULTIVARIATE MODELLING 34
2.7 TYPE LIFELINE CURVE 34
2.8 PRIMARY INTERVIEWS WITH KEY OPINION LEADERS 35
2.9 DBMR MARKET POSITION GRID 36
2.10 MARKET END USER COVERAGE GRID 37
2.11 VENDOR SHARE ANALYSIS 38
2.12 SECONDARY SOURCES 39
2.13 ASSUMPTIONS 39
3 EXECUTIVE SUMMARY 40
4 PREMIUM INSIGHTS 42
4.1 PESTEL ANALYSIS 43
4.2 PORTER'S FIVE FORCES 44
4.3 ASIA PACIFIC BLADDER DISORDERS MARKET, PIPELINE ANALYSIS 45
5 ASIA PACIFIC BLADDER DISORDER MARKET: REGULATIONS 46
5.1 THE U.S. REGULATORY FRAMEWORK FOR BLADDER DISOREDER MEDICATION 46
5.2 EUROPE REGULATORY FRAMEWORK FOR BLADDER DISORDER DRUGS 46
5.3 JAPAN REGULATORY GUIDANCE ON BLADDER DISORDER DRUGS 47
6 ASIA PACIFIC BLADDER DISORDERS MARKET OVERVIEW 49
6.1 DRIVERS 51
6.1.1 STRATEGIC INITIATIVES ADOPTED BY MARKET PLAYERS 51
6.1.2 GROWING GERIATRIC POPULATION 51
6.1.3 RISING R&D INVESTMENTS AND LAUNCH OF NOVEL THERAPIES IN UPCOMING YEARS 52
6.1.4 COMBINATION OF DIFFERENT TARGET THERAPIES 52
6.2 RESTRAINTS 53
6.2.1 HIGH COST ASSOCIATED WITH BLADDER DISORDER DIAGNOSTIC TREATMENT 53
6.2.2 PRODUCTS RECALLS FROM MARKET 53
6.3 OPPORTUNITIES 53
6.3.1 SURGE IN NOVEL TECHNOLOGICAL ADVANCEMENTS 53
6.3.2 RISING DISEASE MANAGEMENT PROGRAMS 54
6.4 CHALLENGES 55
6.4.1 LACK OF AWARENESS ABOUT BLADDER DISORDERS RELATED PROBLEMS 55
6.4.2 PATENT EXPIRY OF DRUGS 55
7 ASIA PACIFIC BLADDER DISORDERS MARKET, BY TYPE 57
7.1 OVERVIEW 58
7.2 OVERACTIVE BLADDER 61
7.3 URINARY INCONTINENCE 61
7.4 CYSTITIS 62
7.5 INTERSTITIAL CYSTITIS 63
7.6 BLADDER CANCER 64
7.7 OTHERS 65
8 ASIA PACIFIC BLADDER DISORDERS MARKET, BY TREATMENT TYPE 66
8.1 OVERVIEW 67
8.2 MEDICATION 70
8.2.1 TOLTERODINE 71
8.2.2 MIRABEGRON 71
8.2.3 FESOTERODINE 71
8.2.4 OXYBUTYNIN 71
8.2.5 SOLIFENACIN 71
8.2.6 DARIFENACIN 71
8.2.7 TROSPIUM 71
8.2.8 OTHERS 72
8.3 SURGERY 72
8.3.1 SURGERY TO INCREASE BLADDER CAPACITY 73
8.3.2 BLADDER REMOVAL 73
8.3.3 OTHERS 73
8.4 OTHERS 73
9 ASIA PACIFIC BLADDER DISORDERS MARKET, BY DISTRIBUTION CHANNEL 75
9.1 OVERVIEW 76
9.2 DIRECT 79
9.3 RETAIL 79
10 ASIA PACIFIC BLADDER DISORDERS MARKET, BY END USER 81
10.1 OVERVIEW 82
10.2 HOSPITALS 85
10.3 CLINICS 86
10.4 AMBULATORY SURGICAL CENTERS 86
10.5 OTHERS 87
11 ASIA PACIFIC BLADDER DISORDERS MARKET, BY GEOGRAPHY 89
11.1 ASIA-PACIFIC 90
11.1.1 CHINA 97
11.1.2 JAPAN 99
11.1.3 INDIA 101
11.1.4 AUSTRALIA 103
11.1.5 SOUTH KOREA 105
11.1.6 THAILAND 107
11.1.7 SINGAPORE 109
11.1.8 INDONESIA 111
11.1.9 MALAYSIA 113
11.1.10 VIETNAM 115
11.1.11 PHILIPPINES 117
11.1.12 REST OF ASIA-PACIFIC 119
12 ASIA PACIFIC BLADDER DISORDERS MARKET: COMPANY LANDSCAPE 120
12.1 COMPANY SHARE ANALYSIS: ASIA PACIFIC 120
13 SWOT ANALYSIS 121
14 COMPANY PROFILE 122
14.1 MERCK AND CO. INC. (2021) 122
14.1.1 COMPANY SNAPSHOT 122
14.1.2 REVENUE ANALYSIS 122
14.1.3 COMPANY SHARE ANALYSIS 123
14.1.4 PRODUCT PORTFOLIO 123
14.1.5 RECENT DEVELOPMENT 123
14.2 ASTELLAS PHARMA INC. (2021) 124
14.2.1 COMPANY SNAPSHOT 124
14.2.2 REVENUE ANALYSIS 124
14.2.3 COMPANY SHARE ANALYSIS 125
14.2.4 PRODUCT PORTFOLIO 125
14.2.5 RECENT DEVELOPMENTS 125
14.3 BRISTOL-MYERS SQUIBB COMPANY (2021) 127
14.3.1 COMPANY SNAPSHOT 127
14.3.2 REVENUE ANALYSIS 127
14.3.3 COMPANY SHARE ANALYSIS 128
14.3.4 PRODUCT PORTFOLIO 128
14.3.5 RECENT DEVELOPMENT 128
14.4 BOSTON SCIENTIFIC CORPORATION (2021) 129
14.4.1 COMPANY SNAPSHOT 129
14.4.2 REVENUE ANALYSIS 129
14.4.3 COMPANY SHARE ANALYSIS 130
14.4.4 PRODUCT PORTFOLIO 130
14.4.5 RECENT DEVELOPMENT 130
14.5 VIATRIS INC. (2021) 131
14.5.1 COMPANY SNAPSHOT 131
14.5.2 REVENUE ANALYSIS 131
14.5.3 COMPANY SHARE ANALYSIS 132
14.5.4 PRODUCT PORTFOLIO 132
14.5.5 RECENT DEVELOPMENT 132
14.6 ABBVIE (2021) 133
14.6.1 COMPANY SNAPSHOT 133
14.6.2 REVENUE ANALYSIS 133
14.6.3 PRODUCT PORTFOLIO 134
14.6.4 RECENT DEVELOPMENT 134
14.7 AXONICS, INC. (2021) 135
14.7.1 COMPANY SNAPSHOT 135
14.7.2 REVENUE ANALYSIS 135
14.7.3 PRODUCT PORTFOLIO 135
14.7.4 RECENT DEVELOPMENT 136
14.8 BLUE WIND MEDICAL (2021) 137
14.8.1 COMPANY SNAPSHOT 137
14.8.2 PRODUCT PORTFOLIO 137
14.8.3 RECENT DEVELOPMENT 137
14.9 COLOPLAST CORP. (2021) 138
14.9.1 COMPANY SNAPSHOT 138
14.9.2 REVENUE ANALYSIS 138
14.9.3 PRODUCT PORTFOLIO 139
14.10 GAYLORD CHEMICAL COMPANY, LLC (2021) 140
14.10.1 COMPANY SNAPSHOT 140
14.10.2 PRODUCT PORTFOLIO 140
14.10.3 RECENT DEVELOPMENT 140
14.11 JOHNSON & JOHNSON SERVICES, INC. (2021) 141
14.11.1 COMPANY SNAPSHOT 141
14.11.2 REVENUE ANALYSIS 141
14.11.3 PRODUCT PORTFOLIO 142
14.11.4 RECENT DEVELOPMENT 142
14.12 KYORIN PHARMACEUTICAL CO., LTD. (A SUBSIDIARY OF KYORIN HOLDINGS, INC.) (2021) 143
14.12.1 COMPANY SNAPSHOT 143
14.12.2 PRODUCT PORTFOLIO 143
14.12.3 RECENT DEVELOPMENTS 144
14.13 LABORIE (2021) 145
14.13.1 COMPANY SNAPSHOT 145
14.13.2 PRODUCT PORTFOLIO 145
14.13.3 RECENT DEVELOPMENT 146
14.14 MEDTRONIC (2021) 147
14.14.1 COMPANY SNAPSHOT 147
14.14.2 REVENUE ANALYSIS 147
14.14.3 PRODUCT PORTFOLIO 148
14.14.4 RECENT DEVELOPMENTS 148
14.15 PFIZER INC. (2021) 149
14.15.1 COMPANY SNAPSHOT 149
14.15.2 REVENUE ANALYSIS 149
14.15.3 PRODUCT PORTFOLIO 150
14.15.4 RECENT DEVELOPMENTS 150
14.16 VALENCIA TECHNOLOGIES (2021) 151
14.16.1 COMPANY SNAPSHOT 151
14.16.2 PRODUCT PORTFOLIO 151
14.16.3 RECENT DEVELOPMENT 152
14.17 SUN PHAMACEUTICAL INDUSTRIES LTD. (2021) 153
14.17.1 COMPANY SNAPSHOT 153
14.17.2 REVENUE ANALYSIS 153
14.17.3 PRODUCT PORTFOLIO 154
14.17.4 RECENT DEVELOPMENT 154
14.18 SWATI SPENTOSE (2021) 155
14.18.1 COMPANY SNAPSHOT 155
14.18.2 PRODUCT PORTFOLIO 155
14.18.3 RECENT DEVELOPMENT 155
14.19 UROVANT SCIENCES (2021) 156
14.19.1 COMPANY SNAPSHOT 156
14.19.2 PRODUCT PORTFOLIO 156
14.19.3 RECENT DEVELOPMENT 156
14.20 ZYDUS GROUP (2021) 157
14.20.1 COMPANY SNAPSHOT 157
14.20.2 PRODUCT PORTFOLIO 157
14.20.3 RECENT DEVELOPMENT 157
15 QUESTIONNAIRE 158
16 RELATED REPORTS 161
Call Us
( India toll free )
+91 835 605 0278
( US toll free )
+1 800 601 6071
Drop us an email at
sales@prudentmarkets.com
Get your pre and post sales queries resolved by our Subject matter experts.
We will assist you to customize the report to fit your research needs.
Our prime focus is to provide qualitative and accurate data.
Feel free to order a sample report before purchase.
Your personal and confidential information is safe and secured.
